Please assess the completion status of the following clinical trial:

Trial Title: To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged between 5 to 65 years (both inclusive).~* Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration and splenomegaly)~* Presence of amastigotes (Leishmania-Donovani bodies) at prescreening detected by rK39 dipstick test with confirmation by splenic or bone marrow aspirate smear examination.~* Non-pregnant, non-lactating females of age ≥5 years, and woman of childbearing potential who are willing to use acceptable methods of contraception~* Negative Urine pregnancy test (UPT) in all women~Exclusion Criteria:~* Patients with past history of treatment with Amphotericin B or any other drug for Visceral Leishmaniasis within 30 days prior to screening.~* Patients positive for HIV, HCV and HBsAg infection, immunocompromised patients (through history).~* Concurrent diabetes, tuberculosis or bacterial pneumonia or any other infectious or major psychiatric disease.~* Pregnant or nursing women~* Patients receiving any of the medications prohibited by the study protocol.~* Simultaneous participation in another trial or received any IP \<30 days prior to enrolment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amphotericin B lipid emulsion (Type: EXPERIMENTAL): Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
- Liposomal Amphotericin B (Type: ACTIVE_COMPARATOR): Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B

Based on this trial design, predict the completion outcome and termination type (if applicable).